Cat.No. : CSC-SC005785 Host Cell: HEK293 (CHO and other cell types are also available)
| Cat. No. | CSC-SC005785 |
| Description | Using Creative Biogene's proprietary lentiviral vectors, we subclone the target gene into lentivector, generate the lentivirus particles, sequentially infect the cell line HEK293 (other cell types are also available according to your requirements), and select the clones constantly expressing target gene at high level. |
| Gene | FLT1 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293 (CHO and other cell types are also available) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Size Form | 2 × 10^6 cells / vial |
| Shipping | Dry Ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Gene Name | FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) [ Homo sapiens ] |
| Gene Symbol | FLT1 |
| Synonyms | FLT; FLT-1; VEGFR1; VEGFR-1 |
| Gene Description | fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) |
| Gene ID | 2321 |
| UniProt ID | P17948 |
| mRNA Refseq | NM_001160031.1 |
| Protein Refseq | NP_001153503.1 |
| Chromosome Location | 13q12 |
| Function | ATP binding; VEGF-A-activated receptor activity; VEGF-B-activated receptor activity; growth factor binding; identical protein binding; placental growth factor-activated receptor activity; protein binding; transmembrane receptor protein tyrosine kinase activity; vascular endothelial growth factor-activated receptor activity; vascular endothelial growth factor-activated receptor activity; |
| Pathway | Angiogenesis, organism-specific biosystem; Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Endocytosis, organism-specific biosystem; Endocytosis, conserved biosystem; Focal Adhesion, organism-specific biosystem; Focal adhesion, organism-specific biosystem; |
| MIM | 165070 |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Identifying new therapeutic targets for radioactive iodine-resistant differentiated thyroid cancer (DTC) patients may help improve the prognosis of I131-resistant DTC patients. Here, researchers explored the potential molecular mechanisms of FLT-1 in DTC. The study showed that FLT1 expression was elevated in thyroid cancer cells that had not received I131 treatment. BHT101 cells overexpressing FLT1 exhibited significantly enhanced proliferation, colony formation, migration, and invasion capabilities. Protein expression of TGFβ1 and p-Smad3 was significantly increased in thyroid cancer cells overexpressing FLT1, while SMAD3 expression showed no significant change. Upregulation of FLT1 led to decreased NIS expression. FOXP3, TGF-βR1, and p-Smad3 were co-localized in FLT1-overexpressing BHT101 cells. In vivo experiments showed that tumor volume and tumor weight increased with increasing FLT1 expression. These results suggest that upregulation of FLT1 can activate the TGF-β1/Smad3 pathway, downregulate NIS expression, and enhance the function of thyroid cancer cells.
Here, researchers investigated the apoptosis, proliferation, migration, invasion, and clonogenic ability of cancer cells after FLT1 upregulation. Both CCK-8 and cell cloning assays showed a significant increase in the proliferation rate of BHT101 cells after FLT1 upregulation (Figure 1A-D). After 24 hours of culture, the wound healing distance of FLT1-overexpressing BHT101 cells was significantly increased (Figure 1C and E). The invasive ability of FLT1-overexpressing cells was also enhanced (Figure 1F and G). No apoptosis was observed in FLT1-overexpressing BHT101 cells (Figure 1H and I).
Figure 1. FLT1 promoted the growth of BHT101 tumors. (Zhuang J, et al., 2025)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
